Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.61), $0.16 better than the analyst estimate of ($1.77). Revenue for the quarter came in at $29.9 million versus the consensus estimate of $17.97 million.

Guidance:

Alnylam reiterates its expectations to end 2018 with approximately $1.0 billion of cash, cash equivalents and marketable debt securities, restricted cash and restricted investments, excluding equity securities.

The Company reiterates its expectations for its 2018 annual non-GAAP R&D expenses to be in the range of $420 million to $460 million and non-GAAP selling, general and administrative (SG&A) expenses to be in the range of $280 million to $320 million. Both non-GAAP R&D and SG&A expenses exclude stock-based compensation expenses.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.